ReviewClinical and experimental immunology2017
Considerations for successful cancer immunotherapy in aged hosts.
Review in Clinical and experimental immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 65 citations in OpenAlex.
- Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age.Oral oncology · 2019Trial
- Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study.Cancer immunology, immunotherapy : CII · 2018Trial
- Age-stratified circulating immune signatures reveal non-invasive biomarkers for colorectal cancer detection.Immunity & ageing : I & A · 2025Article
- Efficacy and safety of immune checkpoint inhibitors in elderly patients with primary liver cancer: a retrospective, multicenter, real-world cohort study.Cancer immunology, immunotherapy : CII · 2023Article
- Immunosenescence, Inflammaging, and Frailty: Role of Myeloid Cells in Age-Related Diseases.Clinical reviews in allergy & immunology · 2023Review
- Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments.Frontiers in immunology · 2023Article
- Association of age with survival in older patients with cutaneous melanoma treated with immune checkpoint inhibitors.Journal of geriatric oncology · 2022Article
- Treatment of Metastatic Melanoma in the Elderly.Current oncology reports · 2022Review
- Hallmarks of Resistance to Immune-Checkpoint Inhibitors.Cancer immunology research · 2022Article
- T cell immune awakening in response to immunotherapy is age-dependent.European journal of cancer (Oxford, England : 1990) · 2022Article
- The comparison of inflammatory markers in geriatric and nongeriatric endometrial cancers.Cancer biomarkers : section A of Disease markers · 2022Article
- Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma.International urology and nephrology · 2022Article
- Review
- Review
- IFN-γ and CD38 in Hyperprogressive Cancer Development.Cancers · 2021Review
- Age-related transcriptome changes in melanoma patients with tumor-positive sentinel lymph nodes.Aging · 2020Article
- Thymic Function Associated With Cancer Development, Relapse, and Antitumor Immunity - A Mini-Review.Frontiers in immunology · 2020Review
- Cutaneous Metastasis after Surgery, Injury, Lymphadenopathy, and Peritonitis: Possible Mechanisms.International journal of molecular sciences · 2019Review
- Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention.Frontiers in immunology · 2019Review
- Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient?Drugs & aging · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Immunotherapy is now experiencing unprecedented successes in treating various cancers based on new understandings of cancer immunopathogenesis. Nonetheless, although ageing is the biggest risk factor for cancer, the majority of cancer immunotherapy preclinical studies are conducted in young hosts. This review will explore age-related changes in immunity as they relate to cancer immune surveillance, immunopathogenesis and responses to immunotherapy. Although it is recognized that declining T cell function with age poses a great challenge to developing effective age-related cancer immunotherapies, examples of successful approaches to overcome this hurdle have been developed. Further, it is now recognized that immune functions do not simply decline with age, but rather change in ways than can be detrimental. For example, with age, specific immune cell populations with detrimental functions can become predominant (such as cells producing proinflammatory cytokines), suppressive cells can become more numerous or more suppressive (such as myeloid-derived suppressor cells), drugs can affect aged immune cells distinctly and the aged microenvironment is becoming recognized as a significant barrier to address. Key developments in these and other areas will be surveyed as they relate to cancer immunotherapy in aged hosts, and areas in need of more study will be assessed with some speculations for the future. We propose the term 'age-related immune dysfunction' (ARID) as best representative of age-associated changes in immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.